207 related articles for article (PubMed ID: 24706111)
1. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.
Fan R; Zhong J; Zheng S; Wang Z; Xu Y; Li S; Zhou J; Yuan F
Clin Exp Med; 2015 May; 15(2):137-44. PubMed ID: 24706111
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT.
Fan R; Zhong J; Zheng S; Wang Z; Xu Y; Li S; Zhou J; Yuan F
Tumour Biol; 2014 May; 35(5):4209-17. PubMed ID: 24375253
[TBL] [Abstract][Full Text] [Related]
3. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
[TBL] [Abstract][Full Text] [Related]
4. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.
Cao W; Yang W; Fan R; Li H; Jiang J; Geng M; Jin Y; Wu Y
Tumour Biol; 2014 Feb; 35(2):1287-95. PubMed ID: 24068565
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
[TBL] [Abstract][Full Text] [Related]
6. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-152 inhibits tumor cell growth while inducing apoptosis via the transcriptional repression of cathepsin L in gastrointestinal stromal tumor.
Lu HJ; Yan J; Jin PY; Zheng GH; Qin SM; Wu DM; Lu J; Zheng YL
Cancer Biomark; 2018 Feb; 21(3):711-722. PubMed ID: 29278883
[TBL] [Abstract][Full Text] [Related]
8. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
9. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
11. Neferine inhibits growth and migration of gastrointestinal stromal tumor cell line GIST-T1 by up-regulation of miR-449a.
Xue F; Liu Z; Xu J; Xu X; Chen X; Tian F
Biomed Pharmacother; 2019 Jan; 109():1951-1959. PubMed ID: 30551450
[TBL] [Abstract][Full Text] [Related]
12. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y
Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
[TBL] [Abstract][Full Text] [Related]
14. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Mahadevan D; Theiss N; Morales C; Stejskal AE; Cooke LS; Zhu M; Kurtzman D; Swart R; Ong E; Qi W
Oncotarget; 2015 Feb; 6(4):1954-66. PubMed ID: 25557174
[TBL] [Abstract][Full Text] [Related]
15. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
Trent JC; Ramdas L; Dupart J; Hunt K; Macapinlac H; Taylor E; Hu L; Salvado A; Abbruzzese JL; Pollock R; Benjamin RS; Zhang W
Cancer; 2006 Oct; 107(8):1898-908. PubMed ID: 16986125
[TBL] [Abstract][Full Text] [Related]
16. The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.
Zhou L; Wang H; Liu H; Huang Z; Wang Z; Zhou X; Mu X
Clin Res Hepatol Gastroenterol; 2022; 46(6):101886. PubMed ID: 35183792
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.
Dupart JJ; Trent JC; Lee HY; Hess KR; Godwin AK; Taguchi T; Zhang W
Mol Cancer; 2009 Nov; 8():99. PubMed ID: 19903356
[TBL] [Abstract][Full Text] [Related]
18. Imatinib Regulates
Huang WK; Shi H; Akçakaya P; Zeljic K; Gangaev A; Caramuta S; Yeh CN; Bränström R; Larsson C; Lui WO
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638938
[TBL] [Abstract][Full Text] [Related]
19. Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.
Consolino L; Longo DL; Sciortino M; Dastrù W; Cabodi S; Giovenzana GB; Aime S
Gastric Cancer; 2017 Jul; 20(4):629-639. PubMed ID: 27995483
[TBL] [Abstract][Full Text] [Related]
20. Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells.
Shima T; Taniguchi K; Tokumaru Y; Inomata Y; Arima J; Lee SW; Takabe K; Yoshida K; Uchiyama K
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
